C4 Therapeutics

C4 Therapeutics

CCCC· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -46.9% in FY2025

Andrew J. Hirsch is the CEO of C4 Therapeutics and was paid $2.9M in FY2025 (Dec), down 44%.

Pay$100 in the stock at the end of FY21 → $6
CEO pay is from each C4 Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Andrew J. HirschFY2025
  2. 2Leonard Reyno, M.D.FY2025
  3. 3Kendra R. AdamsFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

C4 Therapeutics paid its 3 named executives $6.1M in total in FY2025 (Dec). CEO Andrew J. Hirsch was paid $2.9M of that.

Name
Andrew J. HirschPresident & Chief Executive Officer
Leonard Reyno, M.D.Chief Medical Officer
Kendra R. AdamsChief Financial Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers20

See all

The FY2025 (Dec) proxy of C4 Therapeutics names 20 peer companies for pay. Among C4 Therapeutics and these peers, CEO pay was 10th highest of 14 and total shareholder return was 8th highest of 13.

10th highest of 14in C4 Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:

$1.5M$8.5M

8th highest of 13in C4 Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:

$6$15,536

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Activity

  1. Pay
    C4 Therapeutics CEO pay fell 44% to $2.9M. The stock fell 47% in FY2025 (Dec).
    DEF 14A
  2. Pay
    C4 Therapeutics Division head pay fell 29% to $1.6M. The stock fell 47% in FY2025 (Dec).
    DEF 14A
  3. Pay
    C4 Therapeutics CFO pay fell 33% to $1.5M. The stock fell 47% in FY2025 (Dec).
    DEF 14A
  4. Pay
    C4 Therapeutics CEO pay rose 38% to $5.2M. The stock fell 36% in FY2024 (Dec).
    DEF 14A
  5. Pay
    C4 Therapeutics Division head pay rose 38% to $2.3M. The stock fell 36% in FY2024 (Dec).
    DEF 14A
  6. Pay
    C4 Therapeutics CFO pay rose 82% to $2.2M. The stock fell 36% in FY2024 (Dec).
    DEF 14A
  7. Pay
    C4 Therapeutics Chief Scientific Officer pay fell 51% to $1.5M. The stock fell 4% in FY2023 (Dec).
    DEF 14A
  8. Pay
    C4 Therapeutics CEO pay rose 46% to $3.8M. The stock fell 4% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 29, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KFeb 27, 2025FY2024
Proxy statementDEF 14AApr 29, 2024FY2023
Annual report10-KFeb 22, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data